Skip to main content
. 2020 Sep 29;17(4):972–981. doi: 10.1080/21645515.2020.1814097

Table 3.

Positive predictive valuea for concomitant low-grade and high-grade cytology, combined as carcinogenic HPVb, 2 v and 4v HPV Vaccine vaccine-targeted carcinogenic HPV types in combination c, HPV types targeted by 9valent HPV vaccined, 27 non-carcinogenic HPV typesg and age

Age groups 18–23 24–26 27–29 30–34 35–39 40–51 Total
Carcinogenic HPV
 # 860 705 253 253 147 147 2365
 PPV for Low-grade cytology
 95% CI
22.1%
19.4–25.0
20.6%
17.6–23.7
22.1%
17.2–27.8
18.6%
14.0–23.9
19.0%
13.0–26.3
20.4%
14.2–27.8
21.0%
19.3–22.7
 PPV for High-grade cytology
 95% CI
3.0%
2.0–4.4
7.5%
5.7–9.7
9.1%
5.9–13.3
9.1%
5.9–13.3
14.3%
9.1–21.0
7.5%
3.8–13.0
6.6%
5.7–7.7
Carcinogenic HPV types targeted by 2 v HPV or 4v vaccinesc, HPV16,18
 # 372 292 94 84 46 33 921
PPV for Low-grade cytology
95% CI
23.9%
19.7–28.6
20.2%
15.8–25.3
21.3%
13.5–30.9
21.4%
13.2–31.7
15.2%
6.3–28.9
24.2%
11.1–42.3
21.8%
19.2–24.6
PPV for High-grade cytology
95% CI
4.3%
2.5–6.9
12.3%
8.8–16.7
17.0%
10.1–26.2
16.7%
9.4–26.4
21.7%
10.9–36.4
9.1%
1.9–24.3
10.3%
8.4–12.5
Carcinogenic HPV types targeted by 9v vaccinesd, HPV16, 18, 31, 33,45,52,58
 # 668 553 202 181 112 92 1808
 PPV for Low-grade cytology
 95% CI
22.0%
18.9–25.3
21.0%
17.7–24.6
21.8%
16.3–28.1
18.8%
13.4–25.2
23.2%
15.8–32.1
20.7%
12.9–30.4
21.3%
19.5–23.3
 PPV for High-grade cytology
 95% CI
3.4%
2.2–5.1
9.4%
7.1–12.1
10.4%
6.6–15.5
11.0%
6.9–16.5
17.0%
10.5–25.2
9.8%
4.6–17.8
8.0%
6.8–9.3
Remaining carcinogenic HPV types after excluding those targeted by 2v and 4v HPV vaccinese, HPV31,33,35,39,45,51,52,56,58,59,68
 # 488 413 159 169 101 114 1444
 PPV for Low-grade cytology
 95% CI
20.7%
17.2–24.6
20.8%
17.0–25.1
22.6%
16.4–29.9
17.2%
11.8–23.7
20.8%
13.4–30.0
19.3%
12.5–27.7
20.4%
18.4–22.6
 PPV for High-grade cytology
 95% CI
2.0%
1.0–3.7
4.1%
2.4–6.5
4.4%
1.8–8.9
5.3%
2.5–9.9
10.9%
5.6–18.7
7.0%
3.1–13.4
4.3%
3.3–5.5
Remaining carcinogenic HPV types after excluding these HPV types which are targeted by 9v HPV vaccinesf, HPV35,39,51,56,59,68
 # 192 152 51 72 35 55 557
 PPV for Low-grade cytology
 95% CI
22.4%
16.7–29.0
19.1%
13.2–26.2
23.5%
12.8–37.5
18.1%
10.0–28.9
5.7%
0.7–19.2
20.0%
10.4–33
19.7%
16.5–23.3
 PPV for High-grade cytology
 95% CI
1.6%
0.3–4.5
0.7%
0.0–3.6
3.9%
0.5–13.5
4.2%
0.9–11.7
5.7%
0.7–19.2
3.6%
0.4–12.5
2.3%
1.2–4.0
27 non-carcinogenic HPV typesg
 # 551 426 157 135 95 115 1479
 PPV for Low-grade cytology
 95% CI
20.5%
17.2–24.1
20.9%
17.1–25.1
18.5%
12.7–25.4
17.0%
11.1–24.5
16.8%
9.9–25.9
11.3%
6.2–18.6
19.1%
17.2–21.2
 PPV for High-grade cytology
 95% CI
1.3%
0.5–2.6
3.8%
2.2–6.0
3.8%
1.4–8.1
5.2%
2.1–10.4
2.1%
0.3–7.4
4.3%
1.4–9.9
2.9%
2.1–3.9

aPositive predictive value was estimated as the number of specimens of a given cytology category positive to an HPV type (or combination of types) divided by the total number of specimens positive to the same HPV type (or combination of types) irrespective of cytology category.

bCarcinogenic HPV is defined as positive to one of the HPV types 16,18,31,33,35,39,45,51,52,56,58,59,68.

cCarcinogenic HPV types included in 2valent or 4valent HPV vaccine, HPV16, 18

dHPV types included in 9valent HPV vaccine, HPV16,18,31,33,45,52,58

eRemaining of 13 carcinogenic HPV types after removing those targeted by 2valent and 4valent HPV vaccines, HPV31,33,35,39,45,51,52,56,58,59,68

fRemaining of 13 carcinogenic HPV types after removing those targeted by 9valent HPV vaccines, HPV35,39,51,56,59,68

g27 non-carcinogenic HPV is defined as positive to one of the HPV types 6,11,26,30,32,40,42,43,44,53,54,55,61,62,66,67,69,70,73,74,81,83,86,87,89,90,91.

Abbreviations: PPV = Positive predictive value, CI = confidence interval; HPV = human papillomavirus.